Biotechnologist Pharming increases Ruconest sales

0
42


Published on 30 July 2020 07:44 |
Views: 5.408
| Topics: biotechnology

  • items
  • Related instruments
LEIDEN (AFN) – The Leiden biotechnologist Pharming achieved higher turnover and profit in the first half of the year. The company sold more of its primary drug Ruconest and, thanks to a refinance, had lower interest payment costs.

Pharming increased sales by 14 percent to 88.6 million euros. In Europe, the company once again served more markets after the rights to sell Ruconest in certain EU countries were transferred to Pharming as of 1 January. In the United States, sales of the drug for acute hereditary angioedema, or sudden swelling, also increased in the first half of the year. But due to the build-up of large inventories in the first three months of the year, US sales fell by a fifth in the second quarter.

Net profit increased by 33 percent to 18.1 million euros. In addition to the higher sales, Pharming also benefited from cost savings. For example, the company had lower financing costs due to a refinancing with convertible bonds.

For the rest of the year, Pharming expects to further increase sales of Ruconest. In addition, the company will continue to write black figures. Patient recruitment will also start later this year for a larger study into the effect of Ruconest against Covid-19 led by the University Hospital Basel. The administration of the drug to five corona patients yielded “encouraging results” earlier this year.

Related

biotechnology

To follow

Click here to follow this topic and be automatically informed of the latest news.

Pharming Group

To follow

Click here to put this instrument on your watchlist and to be automatically informed of the latest news.

Reactions

To follow

Click here to follow this forum topic and be automatically notified of new posts.

  1. And not unimportant to mention:
    The research is being started not only in Basel but also in Zurich, America and Latin America !!

  2. Good figures and that at this time! The upward trend of recent years continues, Pharming is a company that knows what fighting is all about! I hope that many patients will benefit, it is all about everyone’s health and that is sometimes forgotten when presenting the figures!

  3. It does not state that Q2 was noticeably lower than Q1. For the sake of clarity and that corona did indeed influence the turnover in contrast to what was communicated!

  4. It may never happen again that Pharming’s figures are better than Royal Dutch Shell’s!

  5. Ritageld wrote down 30 july 2020 08:34:

    It may never happen again that Pharming’s figures are better than Royal Dutch Shell’s!

    Maybe next quarter: P again.

  6. huseman1 wrote down 30 july 2020 08:16:

    It does not state that Q2 was noticeably lower than Q1. For the sake of clarity and that corona did indeed influence the turnover in contrast to what was communicated!

    in my view it says: pharming increased sales by 14% to 88.6 million …..

    need new glasses ???

LEAVE A REPLY

Please enter your comment!
Please enter your name here